India's Life Sciences Innovation at a Crossroads: Scaling from Breakthroughs to an Engine of Growth

India’s Life Sciences Sector at a Turning Point

India’s life sciences industry has long been a global supplier of generic medicines, but a new report from Boston Consulting Group (BCG) and HealthKois argues that the country is now at a crossroads: the capacity to innovate exists, but scaling that innovation into a self-sustaining ecosystem remains elusive.

Rising Innovation, Persistent Gaps

Over the past decade, India has made notable strides. Patent filings have increased more than fourfold since 2016, the innovation pipeline has grown by 1.5 times, and the number of biotech startups has risen by a factor of 1.6. Private capital directed toward healthcare innovation reached $731 million in fiscal year 2026, up 2.1 times in five years. Landmark achievements include the FDA approval of Wockhardt’s Zaynich (an intravenous antibiotic) and Pandorum Technologies raising $18 million for exosome-based therapies. Indigenous CAR-T therapies now treat patients at a fraction of global costs.

Yet the report, titled “India Pharma and Life Sciences Innovation Opportunity,” describes the country’s innovation story as “early and uneven.” Most progress is concentrated in late-stage translation, while early-stage research remains underfunded. Public grants for life sciences R&D are typically around $52,000, compared with $2 million to $3 million in the United States or European Union. Clinical trial approvals take roughly 90 days, versus about 30 days in the US. Domestic supply chains for critical raw materials—especially for advanced modalities like gene therapy—are weak, forcing reliance on imports with 30- to 45-day lead times.

Structural Constraints on Scaling

Beyond funding and regulation, the report identifies a low risk appetite among Indian venture capital firms for biotech investments. This limits the availability of early-stage capital, which is crucial for translating academic discoveries into commercial products. Additionally, the talent pipeline in R&D and innovation is uneven: while India produces many scientists, the quality of specialized skills in areas such as clinical development and regulatory affairs remains a bottleneck.

The findings underscore a broader challenge facing emerging economies in the life sciences: moving from generics to novel therapeutics requires not only scientific capacity but also an enabling ecosystem of finance, regulation, infrastructure, and human capital.

Development Impact

India’s life sciences sector has direct implications for economic development and public health. The industry already employs millions and contributes significantly to exports. Accelerating innovation could create high-value jobs, reduce healthcare costs domestically, and position India as a hub for affordable biologics and cell therapies. However, without addressing structural gaps, the country risks remaining a follower rather than a leader in next-generation treatments.

The impact extends to other Global South countries. India’s cost-effective manufacturing and clinical trial capabilities can support global health equity—for example, through affordable CAR-T therapies. But import dependence and slow regulatory processes limit its ability to scale rapidly for both domestic and international markets.

Global South Perspective

India’s experience resonates across the Global South. Many emerging economies possess pockets of scientific excellence but lack the supportive infrastructure to commercialize innovation. South-South cooperation could facilitate knowledge sharing on regulatory harmonization, pooled procurement, and joint investment in supply chains. India’s progress—and its challenges—offer lessons for countries like Brazil, South Africa, and Indonesia that are seeking to build their own life sciences capabilities.

Regional cooperation within the Global South, such as through the BRICS framework, may also help address common constraints, such as access to capital and technology transfer. For India, closer ties with other emerging markets could accelerate clinical trials and expand market access for novel therapies.

Future Outlook and Policy Recommendations

The report outlines five key areas for action over the next 5–10 years:

1. Building specialist biotech capital: Creating dedicated funds and risk-sharing mechanisms to attract more private investment into early-stage biotech.
2. Encouraging academia-industry partnerships: Strengthening collaborations between universities and companies to move research from bench to bedside.
3. Fast-track regulatory pathways: Reducing clinical trial approval times to global benchmarks (e.g., 30 days) and streamlining processes for novel therapies.
4. Domestic supply chain development: Investing in local production of research-grade reagents and raw materials to reduce import dependence.
5. Bridging the talent gap: Upgrading curricula and providing specialized training in clinical research, regulatory science, and biomanufacturing.

If implemented, these measures could transform India’s life sciences sector into a durable innovation engine. The global shift toward personalized medicine and biologics presents a window of opportunity. With policy coherence and sustained investment, India could emerge as a leading player in the next wave of biomedical innovation.

Conclusion

India’s life sciences sector has reached an inflection point. The raw ingredients for innovation are present, but scaling requires a deliberate effort to close structural gaps. As the BCG-HealthKois report makes clear, the choice is between incremental progress and transformative growth. For a country aspiring to become a global innovation hub, the path forward demands strategic policy action and a long-term commitment to building an ecosystem that turns breakthroughs into lasting economic and social value.